CD8A and neoplasm: Specifically, Pagès and colleagues demonstrated the prognostic value of the Immunoscore for time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) in 2681 patients with stage I–III colon cancer by evaluating the total number of tumor-infiltrating T cells and the number of cytotoxic tumor-infiltrating T cells (density of CD3 and CD8 T cell effectors) [12].